ADMA Biologics, Inc.

NASDAQ:ADMA

Biotechnology

Healthcare
$13.56 +0.42%

+$0.04 today

Market cap
$3.01B
Beta
0.73
P/E (TTM)
12.1
EPS (TTM)
$0.70
52W Low $7.21High $20.46

Volume 3.17M

Average 7.07M

ADMA Common Stock

The par or stated value of issued common shares, plus paid-in capital where reported together.

ADMA Biologics, Inc.NASDAQ: ADMA

Common Stock · Q2 FY2026 · quarter ended Jun 2026

Common stock broadly unchanged from a year ago

Common stock stood at $24K at the end of Q2 FY2026, up 0.0% from a year earlier and up 0.0% from the prior quarter. Over 3 fiscal years it compounded at +2.9% a year.

Context

  • Common stock amounted to 0.0% of total assets at the end of Q2 FY2026, unchanged from a year earlier.
  • Common stock increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether common stock keeps rising in the next quarterly balance sheet after a +0.0% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$24K+0.0% QoQ
Last fiscal yearDec 2025
$24K+0.0% YoY
Year agoJun 2025
$24K+0.0% since
Common Stock past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+0.0%——
1 year+0.0%——
3-year CAGR+2.9%——
5-year CAGR——
10-year CAGR——

Common Stock history

USD · from the balance sheet

Latest · FY2025
24K USD
Year-over-year change
+0.0%
4-year CAGR
+5.2%

Common Stock vs competitors

How ADMA compares with its peers on the latest reported figures

  • Peers report in different currencies, so common stock is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +0.0% is the lowest of 4, against a peer median of +2.0%.
  • Common stock amounts to 0.0% of total assets for ADMA, versus a peer median of 0.6%.
ADMA Competitors
Common Stock for ADMA and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ABUSArbutus Biopharma CorporationMar 2026$1.44B USD+2.0%+2.5%521.2%
GRFSGrifols, S.A.Jun 2026€120M EUR+0.3%+0.1%0.6%
IVVDInvivyd, Inc.Mar 2026$28K USD+133.3%+36.5%0.0%
ADMAADMA Biologics, Inc.Jun 2026$24K USD+0.0%+2.9%0.0%
Peer median (excluding ADMA) —+2.0%+2.5%0.6%

Competitors are the stored peer set for ADMA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents51.09M86.52M51.35M103.15M87.63M
Short-term Investments00000
Net Receivables28.58M15.51M27.42M50M158.43M
Inventory124.72M163.28M172.91M170.24M206.47M
Other Current Assets05.1M5.33M8.03M13.99M
Total Current Assets208.73M270.4M257.01M331.41M466.51M
Property, Plant & Equipment (Net)58.2M68.75M63.47M63.34M71.71M
Goodwill3.53M3.53M3.53M3.53M3.53M
Intangible Assets1.73M1.01M499K460K632K
Long-term Investments00000
Tax Assets00084.28M73.26M
Other Non-current Assets4.07M4.77M4.67M5.66M8.6M
Total Non-current Assets67.52M78.06M72.17M157.27M157.73M
Total Assets276.25M348.46M329.18M488.68M624.24M
Account Payables12.43M13.23M15.66M20.22M22.52M
Short-term Debt00002.81M
Tax Payables0003.48M0
Deferred Revenue142.83K143K182K143K0
Other Current Liabilities16.05M1.8M2.37M1.85M6.82M
Total Current Liabilities30.38M39.27M49.81M55.54M69.54M
Long-term Debt94.87M142.83M130.59M72.34M69.33M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)1.98M1.83M1.69M1.55M1.41M
Other Non-current Liabilities397.35K1.85M2.11M1.67M0
Total Non-current Liabilities104.7M157.22M144.17M84.12M77.38M
Total Liabilities135.08M196.49M193.98M139.66M146.92M
Common Stock19.58K22K23K24K24K
Retained Earnings(412.11M)(478.02M)(506.26M)(308.58M)(161.65M)
Accumulated OCI00000
Other Stockholders Equity00000
Minority Interest00000
Total Equity141.17M151.97M135.21M349.02M477.32M
Total Debt102.92M154.44M141.42M82.12M79.89M
Net Debt51.83M67.92M90.07M(21.03M)(7.75M)

ADMA Biologics, Inc.

NASDAQ:ADMA

Intrinsic Alpha fair value

Locked

Current Price

$13.56

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.